KR20160013068A - 세니크리비록 조성물 및 이들을 만들고 이용하는 방법 - Google Patents

세니크리비록 조성물 및 이들을 만들고 이용하는 방법 Download PDF

Info

Publication number
KR20160013068A
KR20160013068A KR1020157035069A KR20157035069A KR20160013068A KR 20160013068 A KR20160013068 A KR 20160013068A KR 1020157035069 A KR1020157035069 A KR 1020157035069A KR 20157035069 A KR20157035069 A KR 20157035069A KR 20160013068 A KR20160013068 A KR 20160013068A
Authority
KR
South Korea
Prior art keywords
composition
weight
salt
lamivudine
fillers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157035069A
Other languages
English (en)
Korean (ko)
Inventor
마크 마이클 멘닝
션 마크 달지엘
Original Assignee
토비라 쎄라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51898872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20160013068(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 토비라 쎄라퓨틱스, 인크. filed Critical 토비라 쎄라퓨틱스, 인크.
Publication of KR20160013068A publication Critical patent/KR20160013068A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157035069A 2013-05-15 2014-05-15 세니크리비록 조성물 및 이들을 만들고 이용하는 방법 Ceased KR20160013068A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361823766P 2013-05-15 2013-05-15
US61/823,766 2013-05-15
PCT/US2014/038211 WO2014186581A1 (en) 2013-05-15 2014-05-15 Cenicriviroc compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
KR20160013068A true KR20160013068A (ko) 2016-02-03

Family

ID=51898872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157035069A Ceased KR20160013068A (ko) 2013-05-15 2014-05-15 세니크리비록 조성물 및 이들을 만들고 이용하는 방법

Country Status (17)

Country Link
US (1) US20160081985A1 (enExample)
EP (1) EP2996694A4 (enExample)
JP (1) JP6391674B2 (enExample)
KR (1) KR20160013068A (enExample)
CN (1) CN105263498B (enExample)
AU (1) AU2014265327B2 (enExample)
BR (1) BR112015028644A2 (enExample)
CA (1) CA2911212A1 (enExample)
CL (1) CL2015003346A1 (enExample)
IL (1) IL242394B (enExample)
MX (1) MX383706B (enExample)
MY (1) MY180145A (enExample)
PH (1) PH12015502539A1 (enExample)
RU (1) RU2633069C2 (enExample)
SG (2) SG10201708595YA (enExample)
UA (1) UA115807C2 (enExample)
WO (1) WO2014186581A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR034985A1 (es) 2001-08-08 2004-03-24 Takeda Chemical Industries Ltd Compuesto biciclico; produccion y uso del mismo
BR112016021682A2 (pt) * 2014-03-21 2018-06-26 Tobira Therapeutics, Inc. cenicriviroc para o tratamento da fibrose
SG10201902137PA (en) * 2014-09-12 2019-04-29 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
KR20170097735A (ko) * 2014-12-23 2017-08-28 토비라 쎄라퓨틱스, 인크. 세니크리비록 및 관련된 유사체들을 만드는 공정
AU2015382376B2 (en) * 2015-02-10 2021-07-01 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
WO2016135740A1 (en) * 2015-02-23 2016-09-01 Natco Pharma Limited Process for preparing stable oral compositions of everolimus
CA2998509A1 (en) * 2015-09-16 2017-03-23 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
SG11201811140UA (en) * 2016-06-21 2019-01-30 Tobira Therapeutics Inc Purified cenicriviroc and purified intermediates for making cenicriviroc
EP3496718A4 (en) * 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
SG11201901438VA (en) 2016-08-31 2019-03-28 Tobira Therapeutics Inc Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
SG11201910191RA (en) 2017-05-11 2019-11-28 Univ King Abdullah Sci & Tech A peptide capable of forming a gel for use in tissue engineering and bioprinting
EP4215600A1 (en) 2017-05-11 2023-07-26 King Abdullah University of Science and Technology Device and method for microfluidics-based 3d bioprinting
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
WO2021133811A1 (en) * 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
EP4093380A1 (en) 2020-01-23 2022-11-30 Lupin Limited Pharmaceutical compositions of raltegravir
US12109327B2 (en) 2020-08-20 2024-10-08 King Abdullah University Of Science And Technology Scaffolds from self-assembling tetrapeptides support 3D spreading, osteogenic differentiation and angiogenesis of mesenchymal stem cells
US11673324B2 (en) 2020-08-20 2023-06-13 King Abdullah University Of Science And Technology Nozzle for 3D bioprinting
JP2022108727A (ja) * 2021-01-13 2022-07-26 日曹商事株式会社 フマル酸含有固形製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2167649C2 (ru) * 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
JP3995414B2 (ja) * 1997-10-20 2007-10-24 大日本住友製薬株式会社 安定な医薬組成物
CA2244097A1 (en) * 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
US6858230B1 (en) * 1999-04-12 2005-02-22 Shionogi & Co., Ltd. Process for producing medicinal composition of basic hydrophobic medicinal compound
JPWO2006059716A1 (ja) * 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
MA34215B1 (fr) * 2010-04-02 2013-05-02 Phivco 1 Llc Traitement d'association comprenant un antagoniste du récepteur ccr5, un inhibiteur de la protéase du vih-1 et un accélérateur pharmacocinétique
BR112016021682A2 (pt) * 2014-03-21 2018-06-26 Tobira Therapeutics, Inc. cenicriviroc para o tratamento da fibrose

Also Published As

Publication number Publication date
AU2014265327A1 (en) 2015-11-26
PH12015502539B1 (en) 2016-02-22
CA2911212A1 (en) 2014-11-20
SG11201509136YA (en) 2015-12-30
WO2014186581A1 (en) 2014-11-20
CN105263498A (zh) 2016-01-20
IL242394B (en) 2019-05-30
PH12015502539A1 (en) 2016-02-22
HK1214171A1 (zh) 2016-07-22
RU2633069C2 (ru) 2017-10-11
CL2015003346A1 (es) 2016-09-16
JP6391674B2 (ja) 2018-09-19
SG10201708595YA (en) 2017-11-29
MX2015015500A (es) 2016-08-11
RU2014150327A (ru) 2016-07-10
EP2996694A1 (en) 2016-03-23
BR112015028644A2 (pt) 2017-07-25
UA115807C2 (uk) 2017-12-26
MY180145A (en) 2020-11-23
US20160081985A1 (en) 2016-03-24
CN105263498B (zh) 2019-04-26
NZ713981A (en) 2021-03-26
MX383706B (es) 2025-03-14
AU2014265327B2 (en) 2019-08-15
EP2996694A4 (en) 2016-12-07
JP2016518452A (ja) 2016-06-23

Similar Documents

Publication Publication Date Title
KR20160013068A (ko) 세니크리비록 조성물 및 이들을 만들고 이용하는 방법
AU2019204689B2 (en) Solid dosage forms of palbociclib
KR101923103B1 (ko) 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물
CN103282036B (zh) 用于治疗骨髓纤维化的组合物和方法
TW202332423A (zh) 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US20110136883A1 (en) Granulation of active pharmaceutical ingredients
EP2531179A1 (en) Pharmaceutical composition comprising n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
WO2009047565A2 (en) Composition 064
EP2440191A2 (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
US20250009751A1 (en) Formulations of antiviral compounds
TW202408531A (zh) 包含葡萄糖酸內酯之哌柏西利製劑
RU2759544C1 (ru) Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции
KR20170113463A (ko) 안정성 및 용출율이 개선된 타다라필 및 탐수로신 함유 캡슐 복합제제
NZ713981B2 (en) Cenicriviroc compositions and methods of making and using the same
HK1214171B (zh) 賽尼克韋羅組合物及其製備和使用方法
TW202224681A (zh) 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物
TR2023006078T2 (tr) Favi̇pi̇ravi̇ri̇n hemen salimli kompozi̇syonu
HK1255654A1 (en) Compositions and methods for treating myelofibrosis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151210

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190514

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200723

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210528

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220117

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210528

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20200723

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I